Welcome to our dedicated page for Nascent Biotech news (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech stock.
About Nascent Biotech (NBIO)
Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotechnology company specializing in the development of human monoclonal antibodies for the treatment of various cancers. Founded in 2014, the company is pioneering immunotherapy solutions to address critical unmet medical needs, with a primary focus on brain and pancreatic cancers. Its lead candidate, Pritumumab (PTB), is a human monoclonal antibody currently in Phase II clinical trials for the treatment of brain cancer, including glioblastomas, one of the most aggressive and challenging forms of cancer to treat.
Core Technology and Scientific Approach
Nascent Biotech’s innovative approach is rooted in the science of immunotherapy, which seeks to harness and modulate the body’s natural immune response to fight disease. The company’s expertise lies in monoclonal antibodies (mAbs), which are highly specific proteins designed to bind to unique antigens on the surface of cancer cells. Pritumumab, for instance, targets a proprietary antigen expressed on cancer cells, enabling precise and effective treatment while minimizing damage to healthy tissues. This targeted approach distinguishes Nascent Biotech in the competitive oncology landscape.
Pipeline and Clinical Advancements
Nascent Biotech’s clinical development is centered on Pritumumab, which has demonstrated promising safety and efficacy results in Phase I trials. These trials showed no dose-related toxicities and highlighted significant tumor shrinkage in some patients, particularly those with glioblastomas. The ongoing Phase II trials aim to evaluate clinical outcomes further, including monotherapy and combination therapies with chemotherapy and checkpoint inhibitors. Additionally, the company is exploring expanded access trials to assess Pritumumab’s potential in treating other cancers, such as pancreatic and colorectal cancers.
Innovative Drug Delivery Mechanisms
In collaboration with HypoSpray Pharma, Nascent Biotech is working to develop alternative delivery systems for Pritumumab. This partnership aims to eliminate the need for bi-weekly infusion treatments, offering patients a more convenient, transdermal or transmucosal drug delivery option. Such innovations not only improve patient quality of life but also enhance the accessibility and scalability of cancer treatments.
Market Position and Competitive Landscape
Nascent Biotech operates in the highly competitive and rapidly evolving field of oncology-focused biotechnology. Its focus on hard-to-treat cancers like glioblastomas and pancreatic cancer positions it within a niche market with significant unmet needs. Competitors include other biotech firms specializing in immunotherapy, such as those developing CAR-T therapies, checkpoint inhibitors, and other monoclonal antibodies. Nascent Biotech differentiates itself through its proprietary antigen-targeting technology and its emphasis on innovative drug delivery solutions.
Challenges and Opportunities
As a clinical-stage company, Nascent Biotech faces challenges typical of its industry, including securing funding for ongoing trials, navigating complex regulatory pathways, and achieving commercial viability. However, its focus on high-value targets, such as brain and pancreatic cancers, and its commitment to innovation provide significant opportunities for growth and partnerships. The company’s Orphan Drug Designation for pancreatic cancer further underscores its potential to address critical medical needs in underserved markets.
Conclusion
Nascent Biotech represents a compelling player in the biotechnology sector, leveraging its expertise in monoclonal antibody development to tackle some of the most challenging cancers. With a strong scientific foundation, innovative partnerships, and a focus on patient-centered solutions, the company is well-positioned to make meaningful contributions to the field of oncology. Its ongoing clinical advancements and collaborative efforts highlight its commitment to improving patient outcomes and addressing unmet medical needs.
Nascent Biotech (OTCQB:NBIO) announced a Notice of Allowance from the USPTO for its lead candidate Pritumumab. This approval, related to patent application 17/515,010, secures broad protections for Pritumumab and its clinical storage conditions. Pritumumab is a naturally-derived antibody designed to target vimentin-expressing tumors, offering a novel approach to treatment that minimizes damage to healthy cells. The patent's allowance is a pivotal step for Nascent in establishing itself in the market of brain cancer therapeutics.
Nascent Biotech (OTCQB:NBIO) has completed the third cohort in its Phase I clinical trial for Brain Cancer, advancing toward the fourth and potentially final cohort. Although the third cohort took longer than expected, the data is deemed useful for future directions. Patient enrollment is ongoing, and the company plans to conduct pharmacokinetic studies to assess the need for a fifth cohort. Pritumumab (PTB) is a targeted immunotherapy designed to selectively target cancer cells without harming healthy cells, marking a significant advancement in cancer treatment.
Nascent Biotech (OTCQB:NBIO) announced that its CEO, Sean Carrick, was interviewed by Proactive Investors, discussing the company's progress with its Phase I Clinical Trial for Pritumumab (PTB), a monoclonal antibody targeting cancers originating in epithelial cells. Carrick emphasized the company's ongoing development of PTB, with plans to advance to Phase II trials, which could significantly benefit shareholders. The interview highlighted milestones achieved in monoclonal antibody development and a vaccine platform utilizing r-BCG to combat viral infections.
Nascent Biotech has announced a partnership with BioTools, focusing on the monoclonal antibody Pritumumab (PTB), aimed at treating brain cancer. This collaboration leverages BioTools' advanced ROA laser-based technology to enhance the characterization of PTB's higher-order molecular structure, potentially improving its effectiveness and applications. PTB, currently in Phase I clinical trials, is expected to benefit from BioTools' expertise in biologic characterization, aiding in the optimization of its pharmaceutical properties.
Nascent Biotech has partnered with Sharp HealthCare to initiate a Phase I clinical trial for Pritumumab (PTB), an innovative immunotherapy targeting glioblastoma, a severe brain cancer. This trial is designed to explore Pritumumab's efficacy against brain tumors and has potential implications for treating other epithelial cancers. Sharp HealthCare's robust cancer program is a key asset in this collaboration. The trial reflects a commitment to addressing significant unmet medical needs in oncology, with an estimated 23,000 new GBM cases annually in the U.S.
Nascent Biotech has received a milestone payment of USD $750,000 from BioRay Pharmaceutical as part of their licensing agreement for the monoclonal antibody Pritumumab. This payment marks the second of four payments totaling USD $5 million, following an initial USD $1 million received in April 2021. The next payment of USD $2.5 million is contingent upon FDA approval for a Phase 2 clinical trial, with the final USD $750,000 due upon trial commencement. Pritumumab is currently in Phase 1 trials targeting brain cancer.
Nascent Biotech (OTCQB:NBIO) has completed dosing for the second cohort in its Phase I trial evaluating Pritumumab (PTB) as a treatment for brain cancer. This achievement allows the company to advance to its third cohort, anticipated to commence shortly. PTB is a targeted immunotherapy designed to specifically attack cancer cells without harming healthy cells. Positive data trends have been reported, paving the way for a future petition for Phase 2 testing. The company continues to push forward in its mission to develop innovative cancer treatments.
Nascent Biotech (OTCQB:NBIO) and its partner, Manhattan BioSolutions, have reported promising preclinical results for a COVID-19 vaccine candidate based on a modified BCG vaccine originally developed for tuberculosis. The vaccine, termed BCG-S, demonstrated significant cellular immune responses in mice, indicating potential effectiveness. Moving forward, additional experiments will investigate the protective efficacy of this vaccine. Both companies express optimism about their collaboration and aim to advance innovative therapies to improve patient outcomes.
Nascent Biotech (OTCQB: NBIO) announced the release of an analyst report by Marble Arch Research, which rates the stock a Speculative Buy with a target price of $0.39 to $1.99. The report emphasizes the potential for significant market value growth as the company's lead drug, Pritumumab (PTB), progresses through clinical trials. Currently, PTB is in an FDA-approved Phase I trial targeting primary and metastatic brain cancer. The CEO expressed optimism for future developments in treating cancers and viral infections.
Nascent Biotech (OTCQB:NBIO) has commenced enrollment for the second cohort in its Phase I trial for treating Brain Cancer with its lead candidate, Pritumumab (PTB). This trial milestone allows for tripling dosage levels over the first cohort, targeting the highest dose without toxicity. PTB, a natural human antibody, targets Cell surface Vimentin to specifically attack cancer cells, sparing healthy ones. The ongoing Phase I trial signifies advancements in targeted immunotherapy, with development for COVID-19 also underway.
FAQ
What is the current stock price of Nascent Biotech (NBIO)?
What is the market cap of Nascent Biotech (NBIO)?
What does Nascent Biotech specialize in?
What is Pritumumab?
How does Nascent Biotech differentiate itself in the biotech industry?
What challenges does Nascent Biotech face?
What are monoclonal antibodies?
What is the significance of Nascent Biotech’s collaboration with HypoSpray Pharma?
What cancers is Nascent Biotech targeting?
What is the status of Pritumumab’s clinical trials?
Does Nascent Biotech have any special designations for its treatments?
What is immunotherapy?
